Shanghai Junshi Biosciences is the largest aerosol gel media manufacturer in China. Previously NMPA approved foreign anti-PD-1 treatment by Opdivo and Keytruda. Recently Shanghai Junshi Biosciences has received approval by NMPA for treatment by using anti-PD-1 to kill cancer cells by boosting the immune system. Skin melanoma has been killing 20,000 people annually in China and foreign anti-PD-1 treatment using troipalimab is a hope for them. National Medical Product Administration has approved Troipalimab to fight against skin cancer.
It has been prepared at the domestic level and is such an innovation that might help the development of biopharmaceutical companies. Resources like technology, capital and talent helped domestic level achievements in bio-pharmaceuticals before biomedicine became prominent. Apart from these domestic level companies have shown great abilities in gene testing, immune therapies, and production of vaccines.
Not only Junshi Biosciences but Innovent Biologics Inc and Jiangsu Hengrui have also dedicated their time to innovative drugs. Shi Lichen says that Chinese bio-pharmaceuticals are behind other multinational pharmaceuticals in chemical drug sector, “the approval of first Chinese Anti-PD-1 treatment just proved that.”
Troipalimab is successful as it has helped patients with melanoma to recover that didn’t show a response to any previous treatments. Objective response rate, disease control rate and one-year survival rates as told by NMPA are 17.3, 57.5 and 69.3% respectively.
Chinese media reports that in China above 50 anti-PD-1 products have filed for approval. 20 new drugs are also in pipeline for approval.
Though many companies are striving to give better immuno-oncology drugs some efforts would also be wasted as many of them may discover duplicate products. Along with this, the competition is increasingly magnificently.